miR-96 induces cisplatin chemoresistance in non-small cell lung cancer cells by downregulating SAMD9

Cisplatin is effective as a single agent or in combination with other drugs for the treatment of non-small cell lung cancer (NSCLC). A concerning clinical challenge with cisplatin-based NSCLC chemotherapy is the intrinsic and acquired chemoresistance to cisplatin. The sterile α motif domain-containi...

Descripción completa

Detalles Bibliográficos
Autores principales: WU, LIN, PU, XINGXIANG, WANG, QIANZHI, CAO, JUN, XU, FANG, XU, LI, LI, KANG
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2016
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4734049/
https://www.ncbi.nlm.nih.gov/pubmed/26893673
http://dx.doi.org/10.3892/ol.2015.4000

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4734049/
https://www.ncbi.nlm.nih.gov/pubmed/26893673
http://dx.doi.org/10.3892/ol.2015.4000

Ejemplares similares